Review article: Strategies for the management of chronic unremitting ulcerative colitis

Alimentary Pharmacology and Therapeutics

Volumn 38, Issue 2, 2013, Pages 77-97

  Mehta, S J ^a   Silver, A R ^a   Lindsay, J O ^a,b  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b ROYAL LONDON HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETARSOL; ACETYLSALICYLIC ACID; ADALIMUMAB; ALICAFORSEN; AZATHIOPRINE; BALSALAZIDE; BECLOMETASONE DIPROPIONATE; BUDESONIDE; CORTICOSTEROID; CYCLOSPORIN A; EPIDERMAL GROWTH FACTOR; GOLIMUMAB; INFLIXIMAB; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NICOTINE; PLACEBO; PREDNISOLONE; TACROLIMUS; TOFACITINIB; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; VEDOLIZUMAB; CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY;

CHRONIC UNREMITTING ULCERATIVE COLITIS; COLON RESECTION; COLONOSCOPY; COMBINATION CHEMOTHERAPY; CORTICOSTEROID THERAPY; CYTAPHERESIS; DIFFERENTIAL DIAGNOSIS; DISEASE ACTIVITY; DOCTOR PATIENT RELATION; DOSAGE SCHEDULE COMPARISON; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; HUMAN; INFORMED CONSENT; LEUCOCYTAPHERESIS; LOW DRUG DOSE; MAINTENANCE THERAPY; PATIENT ATTITUDE; PATIENT COMPLIANCE; PATIENT EDUCATION; PRIORITY JOURNAL; PROCTITIS; PROCTOCOLECTOMY; QUALITY OF LIFE; REFRACTORY PROCTITIS; REMISSION; REVIEW; TREATMENT DURATION; ULCERATIVE COLITIS; UNSPECIFIED SIDE EFFECT; CLINICAL TRIAL (TOPIC); COLITIS, ULCERATIVE; COMPLICATION; TREATMENT OUTCOME;

ADRENAL CORTEX HORMONES; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; CLINICAL TRIALS AS TOPIC; COLECTOMY; COLITIS, ULCERATIVE; CYCLOSPORINE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; REMISSION INDUCTION; TACROLIMUS; TREATMENT OUTCOME;

EID: 84879205424     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.12345     Document Type: Review

References (144)

1. Rubin GP, Hungin AP, Kelly PJ, Ling J., Inflammatory bowel disease: epidemiology and management in an English general practice population. Aliment Pharmacol Ther 2000; 14: 1553.
2. Molodecky NA, Soon IS, Rabi DM, et al,. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology 2012; 142: 46-54.
3. Hou JK, El-Serag H, Thirumurthi S,. Distribution and manifestations of inflammatory bowel disease in Asians, Hispanics, and African Americans: a systematic review. Am J Gastroenterol 2009; 104: 2100-9.
4. Bernklev T, Jahnsen J, Lygren I, et al,. Health-related quality of life in patients with inflammatory bowel disease measured with the short form-36: psychometric assessments and a comparison with general population norms. Inflamm Bowel Dis 2005; 11: 909-18.
5. Janke KH, Raible A, Bauer M, et al,. Questions on life satisfaction (FLZM) in inflammatory bowel disease. Int J Colorectal Dis 2004; 19: 343-53.
6. Rubin DT, Dubinsky MC, Panaccione R, et al,. The impact of ulcerative colitis on patients' lives compared to other chronic diseases: a patient survey. Dig Dis Sci 2010; 55: 1044-52.
7. Ghosh S, Mitchell R,. Impact of inflammatory bowel disease on quality of life: results of the European Federation of Crohn's and Ulcerative Colitis Associations (EFCCA) patient survey. J Crohns Colitis 2007; 1: 10-20.
8. Wilson BS, Lönnfors S, Vermeire S, et al,. The true impact of IBD: a European Crohn's and ulcerative colitis patient life. IMPACT Survey 2010-2011. European Federation of Crohn's and Ulcerative Colitis Associations (EFCCA). Available at: http://efcca.org/media/files/press-Join-Fight/3.PRESS-KIT-IBD- IMPACT-REPORT-BCN.pdf. Accessed November 14, 2012.
9. Cohen RD, Yu AP, Wu EQ, Xie J, Mulani PM, Chao J,. Systematic review: the costs of ulcerative colitis in Western countries. Aliment Pharmacol Ther 2010; 31: 693-707.
10. Eaden JA, Abrams KR, Mayberry JF,. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut 2001; 48: 526-35.
11. Lakatos L, Mester G, Erdelyi Z, et al,. Risk factors for ulcerative colitis-associated colorectal cancer in a Hungarian cohort of patients with ulcerative colitis: results of a population-based study. Inflamm Bowel Dis 2006; 12: 205-11.
12. Winther KV, Jess T, Langholz E, Munkholm P, Binder V,. Long term risk of cancer in ulcerative colitis: a population-based cohort study from Copenhagen County. Clin Gastroenterol Hepatol 2004; 2: 1088-95.
13. Rutter MD, Saunders BP, Wilkinson KH, et al,. Thirty-year analysis of a colonoscopic surveillance program for neoplasia in ulcerative colitis. Gastroenterology 2006; 130: 1030-8.
14. Rutter M, Saunders B, Wilkinson K, et al,. Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. Gastroenterology 2004; 126: 451-9.
15. Cottone M, Scimeca D, Mocciaro F, Civitavecchia G, Perricone G, Orlando A,. Clinical course of ulcerative colitis. Dig Liver Dis 2008; 40 (Suppl. 2): S247-52.
16. Solberg IC, Lygren I, Jahnsen J, et al,. IBSEN Study Group. Clinical course during the first 10 years of ulcerative colitis: results from a population-based inception cohort (IBSEN Study). Scand J Gastroenterol 2009; 44: 431-40.
17. Peyrin-Biroulet L, Khosrotehrani K, Carrat F, et al,. Cesame study group. Increased risk for nonmelanoma skin cancers in patients who receive thiopurines for inflammatory bowel disease. Gastroenterology 2011; 141: 1621-8.
18. Henriksen M, Jahnsen J, Lygren I,. Ulcerative colitis and clinical course: results of a 5-year population-based follow-up study (the IBSEN study). Inflamm Bowel Dis 2006; 12: 543-50.
19. Langholz E, Munkholm P, Davidsen M, Binder V,. Course of ulcerative colitis: analysis of changes in disease activity over years. Gastroenterology 1994; 107: 3-11.
20. Colombel JF, Rutgeerts P, Reinisch W, et al,. Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis. Gastroenterology 2011; 141: 1194-201.
21. Frøslie KF, Jahnsen J, Moum BA,., Vatn MH,; IBSEN Group. Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort. Gastroenterology 2007; 133: 412-22.
22. UK IBD Audit 2006. National results for the organisation and process of IBD care in the UK. Royal College of Physicians of London, 2006
23. Arnott Idr LK, Down C, Rhodes J, et al,. Outcome of acute severe ulcerative colitis: data from the UK National IBD Audit. Gut 2009; 58: A33
24. Mowat C, Cole A, Windsor A, et al,. Guidelines for the management of inflammatory bowel disease in adults. Gut 2011; 60: 571-607.
25. Dignass A, Lindsay JO, Sturm A, et al,. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis: current management. J Crohns Colitis 2012; 6: 991-1030.
26. Lichtenstein GR, Abreu MT, Cohen R, Tremaine W, American Gastroenterological Association. American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Gastroenterology 2006; 130: 940-87.
27. Available at: http://www.ibdstandards.org.uk. Accessed November 30, 2012.
28. Kaplan GG, McCarthy EP, Ayanian JZ, Korzenik J, Hodin R, Sands BE,. Impact of hospital volume on postoperative morbidity and mortality following a colectomy for ulcerative colitis. Gastroenterology 2008; 134: 680-7.
29. Department of Health Long Term Conditions National Service Framework, 2005. Available at: http://www.dh.gov.uk/prod-consum-dh/groups/dh-digitalassets/ @dh/@en/documents/digitalasset/dh-4105369.pdf. Accessed November 30, 2012.
30. Nguyen GC, Kaplan GG, Harris ML, et al,. A national survey of the prevalence and impact of Clostridium difficile infection among hospitalized inflammatory bowel disease patients. Am J Gastroenterol 2008; 103: 1443e50
31. Issa M, Ananthakrishnan AN, Binion DG,. Clostridium difficile and inflammatory bowel disease. Inflamm Bowel Dis 2008; 14: 1432
32. Costa F, Mumolo MG, Bellini M,. Role of faecal calprotectin as non-invasive marker of intestinal inflammation. Dig Liver Dis 2003; 35: 642-7.
33. Kane SV, Sandborn WJ, Rufo PA,. Fecal lactoferrin is a sensitive and specific marker in identifying intestinal inflammation. Am J Gastroenterol 2003; 98: 1309-14.
34. Gisbert JP, Bermejo F, Pérez-Calle JL,. Fecal calprotectin and lactoferrin for the prediction of inflammatory bowel disease relapse. Inflamm Bowel Dis 2009; 15: 1190-8.
35. Cottone M, Pietrosi G, Martorana G, et al,. Prevalence of cytomegalovirus infection in severe refractory ulcerative and Crohn's colitis. Am J Gastroenterol 2001; 96: 773-5.
36. Kandiel A, Lashner B,. Cytomegalovirus colitis complicating inflammatory bowel disease. Am J Gastroenterol 2006; 101: 2857-65.
37. Truelove SC, Witts LJ,. Cortisone in ulcerative colitis; final report on a therapeutic trial. Br Med J 1955; 2: 1041-8.
38. Kane S, Huo D, Aikens J, Hanauer S,. Medication nonadherence and the outcomes of patients with quiescent ulcerative colitis. Am J Gastroenterol 2003; 114: 39-44.
39. Robinson A,. Review article: improving adherence to medication in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2008; 27 (Suppl. 1): 9-14.
40. Goodhand JR, Kamperidis N, Macken L, et al,. Thiopurine non-adherence is more common in adults than adolescents with IBD, and is associated with psychological distress. Gut 2012; 61 (Suppl. 3): A290.
41. Marteau P, Probert CS, Lindgren S, et al,. Combined oral and enema treatment with Pentasa (mesalazine) is superior to oral therapy alone in patients with extensive mild/moderate active ulcerative colitis: a randomised, double blind, placebo controlled study. Gut 2005; 54: 960-5.
42. Safdi M, DeMicco M, Sninsky C, et al,. A double-blind comparison of oral versus rectal mesalamine versus combination therapy in the treatment of distal ulcerative colitis. Am J Gastroenterol 1997; 92: 1867-71.
43. Baron JH, Connell AM, Kanaghinis TG, Lennard-Jones JE, Jones AF,. Out-patient treatment of ulcerative colitis. Comparison between three doses of oral prednisone. Br Med J 1962; 2: 441-3.
44. Sutherland L, Macdonald JK,. Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev 2006; 2: CD000544.
45. Marshall JK, Thabane M, Steinhart AH, Newman JR, Anand A, Irvine EJ,. Rectal 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst Rev (Online) 2010; 1: CD004115.
46. Marshall JK, Irvine EJ,. Rectal corticosteroids versus alternative treatments in ulcerative colitis: a meta-analysis. Gut 1997; 40: 775-81.
47. Gionchetti P, Rizzello F, Venturi A, et al,. Comparison of oral with rectal mesalazine in the treatment of ulcerative proctitis. Dis Col Rectum 1998; 41: 93-9.
48. Andus T, Kocjan A, Müser M, et al,. Clinical trial: a novel high-dose 1 g mesalamine suppository (Salofalk) once daily is as efficacious as a 500-mg suppository thrice daily in active ulcerative proctitis. Inflamm Bowel Dis 2010; 16: 1947-56.
49. Lamet M,. A multicenter, randomized study to evaluate the efficacy and safety of mesalamine suppositories 1 g at bedtime and 500 mg twice daily in patients with active mild-to-moderate ulcerative proctitis. Dig Dis Sci 2011; 56: 513-22.
50. Mulder CJ, Fockens P, Meijer JW, van der Heide H, Wiltink EH, Tytgat GN,. Beclomethasone dipropionate (3 mg) versus 5-aminosalicylic acid (2 g) versus the combination of both (3 mg/2 g) as retention enemas in active ulcerative proctitis. Eur J Gastroenterol Hepatol 1996; 8: 549-53.
51. Rahimi R, Nikfar S, Rezaie A, Abdollahi M,. Comparison of mesalazine and balsalazide in induction and maintenance of remission in patients with ulcerative colitis: a meta-analysis. Dig Dis Sci 2009; 54: 712-21.
52. Marshall JK, Irvine EJ,. Rectal aminosalicylate therapy for distal ulcerative colitis: a meta-analysis. Aliment Pharmacol Ther 1995; 9: 293-300.
53. Marteau P, Crand J, Foucault M, Rambaud JC,. Use of mesalazine slow release suppositories 1 g three times per week to maintain remission of ulcerative proctitis: a randomised double blind placebo controlled multicentre study. Gut 1998; 42: 195-9.
54. D'Albasio G, Paoluzi P, Campieri M, et al,. Maintenance treatment of ulcerative proctitis with mesalazine suppositories: a double-blind placebo-controlled trial. The Italian IBD Study Group. Am J Gastroenterol 1998; 93: 799-803.
55. Ford AC, Achkar JP, Khan KJ, et al,. Efficacy of 5-aminosalicylates in ulcerative colitis: systematic review and meta-analysis. Am J Gastroenterol 2011; 106: 601-16.
56. Hebden JM, Blackshaw PE, Perkins AC, Wilson CG, Spiller RC,. Limited exposure of the healthy distal colon to orally-dosed formulation is further exaggerated in active left-sided ulcerative colitis. Aliment Pharmacol Ther 2000; 14: 155-61.
57. Bouguen G, Roblin X, Bourreille A, et al,. Infliximab for refractory ulcerative proctitis. Aliment Pharmacol Ther 2010; 31: 1178-85.
58. Lawrance IC, Copeland TS,. Rectal tacrolimus in the treatment of resistant ulcerative proctitis. Aliment Pharmacol Ther 2008; 28: 1214-20.
59. Mallon P, McKay D, Kirk S, Gardiner K., Probiotics for induction of remission in ulcerative colitis. Cochrane Database Syst Rev 2007; 4: CD005573.
60. Tursi A, Brandimarte G, Papa A,. Treatment of relapsing mild-to-moderate ulcerative colitis with the probiotic VSL#3 as adjunctive to a standard pharmaceutical treatment: a double-blind, randomized, placebo-controlled study. Am J Gastroenterol 2010; 105: 2218-27.
61. Forbes A, Britton TC, House IM, Gazzard BG,. Safety and efficacy of acetarsol suppositories in unresponsive proctitis. Aliment Pharmacol Ther 1989; 3: 553-6.
62. Breuer RI, Soergel KH, Lashner BA, et al,. Short chain fatty acid rectal irrigation for left-sided ulcerative colitis: a randomised, placebo controlled trial. Gut 1997; 40: 485-91.
63. Sinha A, Nightingale J, West KP, Berlanga-Acosta J, Playford RJ,. Epidermal growth factor enemas with oral mesalamine for mild-to-moderate left-sided ulcerative colitis or proctitis. N Engl J Med 2003; 349: 350-7.
64. Guslandi M, Frego R, Viale E, Testoni PA,. Distal ulcerative colitis refractory to rectal mesalamine: role of transdermal nicotine versus oral mesalamine. Can J Gastroenterol 2002; 16: 293-6.
65. Sandborn WJ, Tremaine WJ, Leighton JA, et al,. Nicotine tartrate liquid enemas for mildly to moderately active left-sided ulcerative colitis unresponsive to first-line therapy: a pilot study. Aliment Pharmacol Ther 1997; 11: 663-71.
66. Green JT, Thomas GA, Rhodes J, et al,. Nicotine enemas for active ulcerative colitis-a pilot study. Aliment Pharmacol Ther 1997; 11: 859-63.
67. Van Deventer SJH, Tami JA, Wedel MK,. A randomised, controlled, double blind, escalating dose study of alicaforsen enema in active ulcerative colitis. Gut 2004; 53: 1646-51.
68. Miner PB Jr, Geary RS, Matson J, et al,. Bioavailability and therapeutic activity of alicaforsen (ISIS 2302) administered as a rectal retention enema to subjects with active ulcerative colitis. Aliment Pharmacol Ther 2006; 23: 1427-34.
69. Bolin TD, Wong S, Crouch R, Engelman JL, Riordan SM,. Appendicectomy as a therapy for ulcerative proctitis. Am J Gastroenterol 2009; 104: 2476-82.
70. Brunel M, Penna C, Tiret E, Balladur P, Parc R,. Restorative proctocolectomy for distal ulcerative colitis. Gut 1999; 45: 542-5.
71. Kane SV, Bjorkman DJ,. The efficacy of oral 5-ASAs in the treatment of active ulcerative colitis: a systematic review. Rev Gastroenterol Dis 2003; 3: 210-8.
72. Hanauer SB, Sandborn WJ, Kornbluth A,. Delayed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: the ASCEND II trial. Am J Gastroenterol 2005; 100: 2478-85.
73. Kamm MA, Sandborn WJ, Gassull M,. Once-daily, high-concentration MMX mesalamine in active ulcerative colitis. Gastroenterology 2007; 132: 66-75.
74. Kruis W, Kiudelis G, Racz I, et al,. Once daily versus three times daily mesalazine granules in active ulcerative colitis: a double-blind, double-dummy, randomised, non-inferiority trial. Gut 2009; 58: 233-40.
75. Sutherland L, Macdonald JK,. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst Rev 2006; 2: CD000543.
76. Lichtenstein GR, Feagan BG, Cohen RD, et al,. Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry. Clin Gastroenterol Hepatol 2006; 4: 621-30.
77. Sherlock ME, Seow CH, Steinhart AH, Griffiths AM,. Oral budesonide for induction of remission in ulcerative colitis. Cochrane Database Syst Rev 2010; 10: CD007698-CD007698.
78. ® extended-release tablets induce remission in patients with mild to moderate ulcerative colitis: results from the CORE I study. Gastroenterology 2012; 143: 1218-26.
79. Travis SP, Danese S, Kupcinskas L, et al,. Once-daily budesonide MMX in active, mild-to-moderate ulcerative colitis: results from the randomised CORE II study. Gut 2013 [Epub ahead of print].
80. Rutgeerts P, Sandborn WJ, Feagan BG, et al,. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005; 353: 2462-76.
81. Panaccione R, Ghosh S, Middleton S, et al,. Infliximab, azathioprine or infliximab + azathioprine for treatment of moderate to severe ulcerative colitis. The UC SUCCESS trial. J Crohn's Colitis 2011; 5: 13
82. Reinisch W, Sandborn WJ, Hommes DW, et al,. Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. Gut 2011; 60: 780-7.
83. Gies N, Kroeker KI, Wong K, Fedorak RN,. Treatment of ulcerative colitis with adalimumab or infliximab: long-term follow-up of a single-centre cohort. Aliment Pharmacol Ther 2010; 32: 522-8.
84. Message L, Bourreille A, Laharie D, et al,. Efficacy of intravenous cyclosporin in moderately severe ulcerative colitis refractory to steroids. Gastroenterol Clin Biol 2005; 29: 231-7.
85. Actis GC, Volpes R, Rizzetto M,. Oral microemulsion cyclosporin to reduce steroids rapidly in chronic active ulcerative colitis. Eur J Gastroenterol Hepatol 1999; 11: 905-8.
86. Ogata H, Matsui T, Nakamura M, et al,. A randomised dose finding study of oral tacrolimus (FK506) therapy in refractory ulcerative colitis. Gut 2006; 55: 1255-62.
87. Ogata H, Kato J, Hirai F, et al,. Double-blind, placebo-controlled trial of oral tacrolimus (FK506) in the management of hospitalized patients with steroid-refractory ulcerative colitis. Inflamm Bowel Dis 2012; 18: 803-8.
88. Schmidt KJ, Herrlinger KR, Emmrich J, et al,. Short-term efficacy of tacrolimus in steroid-refractory ulcerative colitis-experience in 130 patients. Aliment Pharmacol Ther 2013; 37: 129-36.
89. Yamamoto S, Nakase H, Mikami S, et al,. Long-term effect of tacrolimus therapy in patients with refractory ulcerative colitis. Aliment Pharmacol Ther 2008; 28: 589-97.
90. D'Albasio G, Pacini F, Camarri E, et al,. Combined therapy with 5-aminosalicylic acid tablets and enemas for maintaining remission in ulcerative colitis: a randomized double-blind study. Am J Gastroenterol 1997; 92: 1143-7.
91. Yokoyama H, Takagi S, Kuriyama S, et al,. Effect of weekend 5-aminosalicylic acid (mesalazine) enema as maintenance therapy for ulcerative colitis: results from a randomized controlled study. Inflamm Bowel Dis 2007; 13: 1115-20.
92. Timmer A, McDonald JW, Macdonald JK,. Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev 2007; 1: CD000478.
93. Timmer A, McDonald JW, Tsoulis DJ, Macdonald JK,. Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev 2012; 9: CD000478.
94. Ardizzone S, Maconi G, Russo A, Imbesi V, Colombo E, Bianchi PG,. Randomised controlled trial of azathioprine and 5-aminosalicylic acid for treatment of steroid dependent ulcerative colitis. Gut 2006; 55: 47-53.
95. Fraser AG, Orchard TR, Jewell DP,. The efficacy of azathioprine for the treatment of inflammatory bowel disease: a 30 year review. Gut 2002; 50: 485-9.
96. Hawthorne AB, Logan RF, Hawkey CJ, et al,. Randomised controlled trial of azathioprine withdrawal in ulcerative colitis. BMJ 1992; 305: 20-2.
97. Ansari A, Hassan C, Duley J, et al,. Thiopurine methyltransferase activity and the use of azathioprine in inflammatory bowel disease. Aliment Pharmacol Ther 2002; 16: 1743-50.
98. Osterman MT, Kundu R, Lichtenstein GR, Lewis JD,. Association of 6-thioguanine nucleotide levels and inflammatory bowel disease activity: a meta-analysis. Gastroenterology 2006; 130: 1047-53.
99. Haines ML, Ajlouni Y, Irving PM, et al,. Clinical usefulness of therapeutic drug monitoring of thiopurines in patients with inadequately controlled inflammatory bowel disease. Inflamm Bowel Dis 2011; 17: 1301-7.
100. Smith MA, Blaker P, Marinaki AM, Anderson SH, Irving PM, Sanderson JD,. Optimising outcome on thiopurines in inflammatory bowel disease by co-prescription of allopurinol. J Crohns Colitis 2012; 6: 905-12.
101. Lawson MM, Thomas AG, Akobeng AK,. Tumour necrosis factor alpha blocking agents for induction of remission in ulcerative colitis. Cochrane Database Syst Rev 2006; 3: CD005112.
102. Hanauer SB, Feagan BG, Lichtenstein GR, et al,. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002; 359: 1541.
103. Baert F, Noman M, Vermeire S, et al,. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 2003; 348: 601.
104. Seow CH, Newman A, Irwin SP, et al,. Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis. Gut 2010; 59: 49-54.
105. Ferrante M, Vermeire S, Katsanos KH, et al,. Predictors of early response to infliximab in patients with ulcerative colitis. Inflamm Bowel Dis 2007; 13: 123-8.
106. Oussalah A, Evesque L, Laharie D, et al,. A multicenter experience with infliximab for ulcerative colitis: outcomes and predictors of response, optimization, colectomy, and hospitalization. Am J Gastroenterol 2010; 105: 2617-25.
107. Jürgens M, Laubender RP, Hartl F, et al,. Disease activity, ANCA, and IL23R genotype status determine early response to infliximab in patients with ulcerative colitis. Am J Gastroenterol 2010; 105: 1811-9.
108. Sandborn WJ, van Assche G, Reinisch W, et al,. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology 2012; 142: 257-65.
109. Sandborn WJ, Colombel JF, D'Haens G, et al,. One-year maintenance outcomes among patients with moderately-to-severely active ulcerative colitis who responded to induction therapy with adalimumab: subgroup analyses from ULTRA 2. Aliment Pharmacol Ther 2013; 37: 204-13.
110. Oren R, Arber N, Odes S, et al,. Methotrexate in chronic active ulcerative colitis: a double-blind, randomized, Israeli multicenter trial. Gastroenterology 1996; 110: 1416-21.
111. Mate-Jimenez J, Hermida C, Cantero-Perona J, Moreno-Otero R,. 6-mercaptopurine or methotrexate added to prednisone induces and maintains remission in steroid-dependent inflammatory bowel disease. Eur J Gastroenterol Hepatol 2000; 12: 1227-33.
112. Wahed M, Louis-Auguste JR, Baxter LM, et al,. Efficacy of methotrexate in Crohn's disease and ulcerative colitis patients unresponsive or intolerant to azathioprine/mercaptopurine. Aliment Pharmacol Ther 2009; 30: 614-20.
113. Khan KJ, Dubinsky MC, Ford AC, Ullman TA, Talley NJ, Moayyedi P,. Efficacy of immunosuppressive therapy for inflammatory bowel disease: a systematic review and meta-analysis. Am J Gastroenterol 2011; 106: 630-42.
114. Orth T, Peters M, Schlaak JF, et al,. Mycophenolate mofetil versus azathioprine in patients with chronic active ulcerative colitis: a 12-month pilot study. Am J Gastroenterol 2000; 95: 1201-7.
115. Palaniappan S, Ford AC, Greer D, et al,. Mycophenolate mofetil therapy for refractory inflammatory bowel disease. Inflamm Bowel Dis 2007; 13: 1488-92.
116. Sawada K, Kusugami K, Suzuki Y, et al,. Leukocytapheresis in ulcerative colitis: results of a multicenter double-blind prospective case-control study with sham apheresis as placebo treatment. Am J Gastroenterol 2005; 100: 1362-9.
117. Sawada K, Muto T, Shimoyama T, et al,. Multicenter randomized controlled trial for the treatment of ulcerative colitis with a leukocytapheresis column. Curr Pharmaceut Des 2003; 9: 307-21.
118. Sands BE, Sandborn WJ, Feagan B, et al,. A randomized, double-blind, sham-controlled study of granulocyte/monocyte apheresis for active ulcerative colitis. Gastroenterology 2008; 135: 400-9.
119. Thanaraj S, Hamlin PJ, Ford AC,. Systematic review: granulocyte/monocyte adsorptive apheresis for ulcerative colitis. Aliment Pharmacol Ther 2010; 32: 1297-306.
120. Sandborn WJ, Feagan BG, Marano CW, et al,. A phase 2/3 randomized, placebo-controlled, double-blind study to evaluate the safety and efficacy of subcutaneous golimumab induction therapy in patients with moderately to severely active ulcerative colitis: PURSUIT SC. Gastroenterology 2012; 142 (Suppl. 1): S-161
121. Gordon FH, Hamilton MI, Donoghue S, et al,. A pilot study of treatment of active ulcerative colitis with natalizumab, a humanized monoclonal antibody to alpha-4 integrin. Aliment Pharmacol Ther 2002; 16: 699-705.
122. Feagan BG, Greenberg GR, Wild G, et al,. Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin. N Engl J Med 2005; 352 (Suppl. 1): 2499-507.
123. Parikh A, Leach T, Wyant T, et al,. Vedolizumab for the treatment of active ulcerative colitis: a randomized controlled phase 2 dose-ranging study. Inflamm Bowel Dis 2012; 18: 1470-9.
124. Feagan BG, Rutgeerts PJ, Sands BE, et al,. Induction therapy for ulcerative colitis: results of GEMINI I, a randomized, placebo-controlled, double-blind, multicenter phase 3 trial. Gastroenterology 2012; 142, S-160
125. Sandborn WJ, Ghosh S, Panes J,; Study A3921063 Investigators. Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis. N Engl J Med 2012; 367: 616-24.
126. Fazio VW, Kiran RP, Remzi FH, et al,. Ileal pouch anal anastomosis: analysis of outcome and quality of life in 3707 patients. Ann Surg 2013; 257: 679-85.
127. Heikens JT, de Vries J, de Jong DJ, et al,. Evaluation of long-term function, complications, quality of life and health status after restorative proctocolectomy with ileo neo rectal and with ileal pouch anal anastomosis for ulcerative colitis. Colorectal Dis 2013; doi: 10.1111/codi.12175 [Epub ahead of print].
128. Langholz E, Munkholm P, Davidsen M, et al,. Colorectal cancer risk and mortality in patients with ulcerative colitis. Gastroenterology 1992; 103: 1444.
129. Jess T, Riis L, Vind I, et al,. Changes in clinical characteristics, course, and prognosis of inflammatory bowel disease during the last 5 decades: a population-based study from Copenhagen, Denmark. Inflamm Bowel Dis 2007; 13: 481.
130. Hueting WE, Gooszen HG, van Laarhoven CJ,. Sexual function and continence after ileo pouch anal anastomosis: a comparison between a meta-analysis and a questionnaire survey. Int J Colorectal Dis 2004; 19: 215-8.
131. Damgaard B, Wettergren A, Kirkegaard P,. Social and sexual function following ileal pouch-anal anastomosis. Dis Colon Rectum 1995; 38: 286-9.
132. Olsen KO, Joelsson M, Laurberg S, Oresland T,. Fertility after ileal pouch-anal anastomosis in women with ulcerative colitis. Br J Surg 1999; 86: 493-5.
133. Gorgun E, Remzi FH, Goldberg JM, et al,. Fertility is reduced after restorative proctocolectomy with ileal pouch anal anastomosis: a study of 300 patients. Surgery 2004; 136: 795-803.
134. Mortier PE, Gambiez L, Karoui M, et al,. Colectomy with ileorectal anastomosis preserves female fertility in ulcerative colitis. Gastroenterol Clin Biol 2006; 30: 594-7.
135. Andersson P, Söderholm JD,. Surgery in ulcerative colitis: indication and timing. Dig Dis 2009; 27: 335-40.
136. Tekkis PP, Lovegrove RE, Tilney HS, et al,. Long-term failure and function after restorative proctocolectomy: a multi-centre study of patients from the UK national ileal pouch registry. Colorectal Dis 2010; 12: 433
137. Loftus EV, Delgado DJ, Friedman HS, Sandborn WJ,. Colectomy and the incidence of postsurgical complications among ulcerative colitis patients with private health insurance in the United States. Am J Gastroenterol 2008; 103: 1737-45.
138. Ferrante M, D'Hoore A, Vermeire S, et al,. Corticosteroids but not infliximab increase short-term postoperative infectious complications in patients with ulcerative colitis. Inflamm Bowel Dis 2009; 15: 1062-70.
139. Lake JP, Firoozmand E, Kang JC, et al,. Effect of high-dose steroids on anastomotic complications after proctocolectomy with ileal pouch-anal anastomosis. J Gastrointest Surg 2004; 8: 547-51.
140. Subramanian V, Pollok RC, Kang JY, Kumar D,. Systematic review of postoperative complications in patients with inflammatory bowel disease treated with immunomodulators. Br J Surg 2006; 93: 793-9.
141. Zmora O, Khaikin M, Pishori T, et al,. Should ileoanal pouch surgery be staged for patients with mucosal ulcerative colitis on immunosuppressives? Int J Colorectal Dis 2007; 22: 289-92.
142. Yang Z, Wu Q, Wu K, Fan D,. Meta-analysis: pre-operative infliximab treatment and short-term post-operative complications in patients with ulcerative colitis. Aliment Pharmacol Ther 2010; 31: 486-92.
143. Waterman M, Xu W, Dinani A, et al,. Original article: preoperative biological therapy and short-term outcomes of abdominal surgery in patients with inflammatory bowel disease. Gut 2013; 62: 387-94.
144. Yang Z, Wu Q, Wang F, Wu K, Fan D,. Meta-analysis: effect of preoperative infliximab use on early postoperative complications in patients with ulcerative colitis undergoing abdominal surgery. Aliment Pharmacol Ther 2012; 36: 922-8.